Patients with type 2 diabetes mellitus (T2DM) have a progressive disease and are at increased risk for cardiovascular complications and early death if their disease is not managed according to recommended approaches. Because hyperglycemia is a “silent” condition, optimal management involves both patient and clinician in monitoring response to treatment, achieving glycemic goals, and intensifying treatment in a timely manner when goals are not met or disease progresses. This activity takes a case-based approach to exploring management of patients with T2DM, including initiating basal insulin, minimizing hypoglycemia risk, and recommended combinations when patients using basal insulin require additional therapy.
Case studies with interactive benchmarking
To improve primary care management of patients with type 2 diabetes in order to ensure optimal control of hyperglycemia, minimize long-term complications, and reduce hypoglycemia risk through appropriate use of basal insulin.
After completing this activity, participants should be better able to:
- Assess the clinical characteristics of basal insulins and basal insulin analogues
- Select appropriate patients for treatment with basal insulin therapy based on treatment risks and benefits, guideline recommendations, and patient factors
- Implement strategies for achieving glycemic goals in patients with T2DM, while minimizing the risk of hypoglycemia
NPs and PAs
CNE Credit Designation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
PA Planner: Daniel Thibodeau, PA-C, MPH
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until December 19, 2019. PAs should only claim credit commensurate with the extent of their participation.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Novo Nordisk Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Kruger: advisory board: Abbott, Eli Lilly, Janssen, Novo Nordisk, Sanofi Aventis; grants/research support: Abbott, AstraZeneca, Dexcom, Eli Lilly, Helmsley Charitable Trust, Lexicon, Novo Nordisk; speakers bureau: Abbott, AstraZeneca, Boehringer Ingelheim/Lilly, Dexcom, Janssen, Novo Nordisk, Valeritas; stock: Dexcom.
The Planning Committee for this activity included Dan Thibodeau, PA-C, MHP, of Eastern Virginia Medical School, and Ruth Cohen and Leslie Burgess of Continuing Education Alliance. The members of the Planning Committee have no relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the activity in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: December 19, 2018
Expiration date: December 19, 2019
© 2019 Practicing Clinicians Exchange. All Rights Reserved. NPCE94818